Biocon Limited (NSE: BIOCON, BSE: 532523) announced that its wholly-owned subsidiary, Biocon Pharma Limited, has received final approvals from the U.S. Food and Drug Administration (US FDA) for its ANDAs (Abbreviated New Drug Applications) for Lenalidomide capsules and Dasatinib tablets.
The approved Lenalidomide capsules come in strengths of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg, targeting the treatment of multiple myeloma, lymphoma, and anemia in myelodysplastic syndromes. The Dasatinib tablets, approved in 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg strengths, are used to treat Philadelphia chromosome positive chronic myeloid leukemia and acute lymphoblastic leukemia.
Biocon Pharma also received tentative approval for its ANDA for Rivaroxaban Tablets USP, in 2.5 mg, 10 mg, 15 mg and 20 mg strengths. Rivaroxaban is an anticoagulant.
Disclaimer: The information provided is for educational purposes only and does not constitute financial advice. We are not registered financial advisors. Please conduct your own research and consult a qualified advisor before making investment decisions. Any investment decisions you make based on this information are solely at your own risk.
Also read: Suzlon Powers Low CO2 Steel with Expanded 907 MW Jindal Renewables Order
Published on: March 4, 2025 at 09.25PM GMT.
₹2000 Note Exchange Woes for Farmers:
Farmers and rural residents of kodagu are still holding ₹2000 notes facing challenges as nearby banks no longer accept them. Many fear sending notes by post to the RBI, worrying about security and delays, highlighting the need for RBI exchange centers in rural areas.
As stated in Bhagavad Gita :
विद्या ददाति विनयं विनयाद्याती पात्रताम्।
Knowledge gives humility, and from humility comes worthiness.
